GOED News Alerts: Analysis on events affecting EPA and DHA Markets

GOED Submits Authorized Health Claim Petition to FDA 

November 6: GOED has submitted its petition to the U.S. FDA for an authorized health claim for Eicosapentaenoic and Docosahexaenoic Acids and Reduction of Blood Pressure in the General Population. The basis for the GOED petition is a comprehensive meta-analysis of 70 randomized controlled trials, pertaining to EPA+DHA provision and blood pressure reduction. Collectively, the totality of evidence indicates that provision of EPA+DHA significantly reduces both systolic blood pressure and diastolic blood pressure among study participants representative of the general population. The data across all studies are overwhelmingly consistent, suggesting an independent causal relationship.
 
Background
It has been over nine years since the FDA announced that it would allow the following claim to be used on foods and dietary supplements with EPA and DHA: “Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease.

In 2004, when the FDA responded to the health claim petitions (click here and here), high blood pressure was recognized as a surrogate endpoint for coronary heart disease (CHD). More recently, on August 1st of this year, GOED, along with its consultants from Exponent Inc. Health Sciences and Van Elswyk Consulting Inc., visited the FDA and the Agency’s position was confirmed.      
 
What’s Next
Many members have asked what will happen after the petition is submitted. The review process will likely be lengthy, particularly given the number of studies included in the meta-analysis. The FDA was clear when GOED met with the Agency in August that each study included in the meta-analysis will need to be reviewed. Below is a paraphrased version of the timeline provided in 21CFR101.70.
  • Within 15 days of receipt of the petition, the petitioner will be notified that the petition is undergoing review and that the petitioner will be notified of the agency’s decision to file for comprehensive review or deny the petition.
  • Within 100 days of the date of receipt of the petition, the FDA will notify the petitioner that the petition has either been filed for comprehensive review or denied. Assuming the petition is filed, the date of the notification becomes the date of filing. If FDA does not act within 100 days, the petition shall be deemed to be denied unless an extension is mutually agreed upon by FDA and the petitioner.
  • Within 90 days of the date of filing, the FDA will either deny the petition or inform the petitioner that a proposed regulation to provide for the requested use of the health claim will be published in the Federal Register. Assuming the petition proceeds, FDA will publish the proposal to amend the regulations to provide for the requested use of the health claim in the Federal Register within 90 days of the date of filing. The proposal will also announce the availability of the petition for public review. If the FDA does not act within 90 days of the date of filing, the petition shall be deemed to be denied unless an extension is mutually agreed upon by FDA and the petitioner.
  • Within 270 days of the date of publication of the proposal, FDA will publish a final rule that either authorizes use of the health claim or explains why the agency has decided not to authorize one.
  • Note that the FDA may extend, no more than twice, the period in which it will publish a final rule and each such extension will be for no more than 90 days.




More Commentary on the GOED Exchange

GOED Exchange 2014 registration is now open. Take a quick look at what others thought of last year's event — this week's comments are from Aker's Todd Norton — and register now to be part of the action next year, February 4-6 in Salt Lake City.



GOED Schedules Next Two Member Meetings

GOED's next two member meetings will be held in conjunction with upcoming trade shows SupplySide West and Food Ingredients Europe. The meeting at SupplySide West in Las Vegas will take place on Thursday, November 14th from 2:00-3:30 p.m. in Casanova 504-505 at the Venetian Hotel.

The meeting at Food Ingredients Europe in Frankfurt, Germany, will take place on Wednesday, November 20th from 2:00-3:30 p.m. in Room Symmetrie 2 in Hall 8 of Messe Frankfurt. 

 

GOED to Host Omega-3 Pavilion at Fi Asia-China

Due to increasing interest in the region, GOED has partnered with Fi Global to organize an Omega-3 Pavilion at next year's Fi Asia-China show, which takes place June 26-28 in Shanghai, China. There are six positions for GOED members in the pavilion and they are available on a first come, first served basis. If you are interested in receiving more information, please email Mike Roberts.


Membership Update

November 1 — GOED welcomes three new companies to its membership, Henry Lamotte Oils, Trygg Pharma and Savopec-Maromega.

Joining at the Base level is Henry Lamotte Oils, a German refined omega-3 oil supplier for the pharmaceutical, food and feed industries. The main contact is Arne Schwoge, who can be reached at arne.schwoge@lamotte-oils.de.

Savopec-Maromega, a refined fish oil supplier from Morocco, has joined GOED at the Base level. The main contact is Abbouh Mohamed Malainin, who can be reached at m.malainin@kbaholding.com.

Trygg Pharma AS, which joins GOED at the Base level, is a Norwegian late-stage biotechnology company developing investigational, marine-based omega-3 fatty acids for pharmaceutical applications. The main contact is Atle Skattebol, who can be reached at Atle.Skattebol@tryggpharma.com.

Also, Imperial-Oel-Import has changed its membership to Base level.

Twitter Account not yet Authorized
Follow us on Twitter
GOED Exchange
FAB ad
ISSFAL has issued a Call for Abstracts for the 11th Biennial Congress on Fatty Acids and Lipids, which will take place June 28-July 2 in Stockholm, Sweden. To learn more or submit an abstract, please click here.
Linked In
Copyright © 2013 Global Organization for EPA and DHA Omega-3s, All rights reserved.
This content is designed for use by GOED members. It may not be distributed or reprinted without permission from GOED. To request permission, click here.